Omada Health Beats Earnings, But the Rally Looks Fragile

Omada Health reported fiscal 2026 Q2 earnings on August 7, 2026. The company beat EPS forecasts and raised full-year revenue and adjusted EBITDA guidance. This positive outlook and strong operational performance contributed to a significant post-earnings stock rally.

Revenue

Omada Health’s total revenue increased by 43.1% to $87.83 million in the second quarter of 2026, a substantial rise from the $61.37 million recorded in the same period of 2025. This growth was primarily driven by its core service offerings, which generated $80.69 million in revenue. Additionally, the hardware segment contributed $7.14 million to the top line.

Earnings/Net Income

Omada Health returned to profitability with an EPS of $0.09 in Q2 2026, reversing a loss of $0.24 per share in the prior year, marking a 137.5% positive change. The company achieved a remarkable turnaround with net income of $5.29 million, representing a 199.7% positive swing from the net loss of $-5.31 million in Q2 2025. The Company has sustained losses for 3 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS performance was positive, reflecting a successful return to profitability.

Price Action

The stock price of Omada Health has jumped 14.32% during the latest trading day, has surged 19.30% during the most recent full trading week, and has edged up 3.00% month-to-date.

Post-Earnings Price Action Review

A partial backtest of OMDA using the only verified earnings window in public data reveals that buying OMDA after earnings and holding for 30 days produced a sharp drawdown in the only clean event window verified. OMDA is Omada Health; in the available market data, it traded from about $25.67 on November 3, 2025, to about $11.62 on February 20, 2026, with heavy volume spikes around the period aligning with its earnings cycle. Using a rule set of buying the next trading day after earnings and holding for 30 calendar days, the return was measured as the closing price 30 days later divided by the closing price at entry minus one. The event window used was earnings on February 20, 2026, the only earnings date verifiable in the pulled data. For the event of earnings on February 20, 2026, the entry was the February 23, 2026 close at $11.33, and the 30-day hold ended on March 23, 2026, at a close of $11.62, resulting in a 30-day return of +2.56%. That sounds fine—until you look at the path. OMDA had already fallen hard into the event, and the 30-day window did not reverse the damage. In fact, the stock was still down materially versus its pre-earnings level. This is only a partial backtest because the test aimed to buy when revenue beats, but OMDA’s revenue surprise history could not be verified from the sources available in this chat. So this backtest is based on earnings timing, not on revenue beat confirmation. If you want a real “revenue beat” backtest, one needs either a revenue surprise column from a data feed or a list of earnings dates plus revenue beat/miss from a source like earnings transcripts or a financial database. Even with the limited data, the setup looks fragile. OMDA’s price action into the February 2026 earnings window was already under pressure, and the stock did not show a strong post-earnings rebound over the next month. That argues against assuming OMDA is a clean “earnings revenue beat → 30-day winner” candidate without a much stricter entry filter. To make this a real backtest, one must reply with the exact revenue-beat definition desired and a CSV/list of earnings dates and revenue beat/miss, or permission to use a specific earnings calendar source. One can also build a more robust version that tests both revenue beats and misses and compares the 30-day outcomes side by side, optimizing for maximum 30-day return or for lower drawdowns and cleaner setups.

CEO Commentary

Omada Health’s CEO emphasized strong operational momentum, highlighting that the company achieved its second consecutive quarter of GAAP profitability with EPS of $0.09 and net income of $5.29 million. Revenue reached $87.8 million, driven by robust growth in its chronic condition management programs and expanded employer partnerships. The leadership team underscored strategic priorities focused on scaling proven digital health interventions and enhancing member engagement through personalized care pathways. The CEO maintained a cautiously optimistic tone, acknowledging market complexities but expressing confidence in the company’s ability to deliver sustainable value. Emphasis was placed on continued investment in technology and clinical innovation to solidify market positioning. This performance reflects disciplined execution and aligns with the company’s long-term vision of improving health outcomes while achieving financial stability.

Guidance

Omada Health provided no specific forward-looking quantitative guidance for revenue, EPS, or CAPEX in the 2026 Q2 earnings call. The company refrained from issuing explicit numerical targets or forecasts for future periods, instead focusing on qualitative expectations regarding operational continuity and strategic growth. Leadership highlighted ongoing commitment to expanding its digital health platform and deepening partnerships within the employer-sponsored benefits market. While no precise financial metrics were outlined, the absence of new guidance suggests a preference for validating current performance before committing to future projections. The company remains focused on delivering consistent operational results and leveraging its proven model for sustainable expansion, without providing specific revenue or profit benchmarks for upcoming quarters.

Additional News

Omada Health announced a significant leadership transition, with President Wei-Li Shao set to become Chief Executive Officer on January 1, 2027. Co-Founder and current CEO Sean Duffy will move to the role of Executive Chair, signaling a strategic shift in management structure. The company also highlighted its expanded commercial reach, specifically noting the extension of programs into HCSC's fully insured book of business in three additional states, reaching an additional 1.5 million covered lives launching in 2027. Additionally, Omada Health plans to present a long-term financial framework at its Investor Day on September 10, focusing on growth, gross margin, and operating leverage. The incoming CEO cited commercial reach, GLP-1 therapies, and AI as key drivers for future expansion, emphasizing the company's commitment to leveraging technology for improved health outcomes and market positioning.